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ABSTRACT 
Objective: The aim of the present work was to develop new solid pharmaceutical delivery systems of mesalazine (5-aminosalicylic acid, 5-ASA) for 
its colon targeted release.  
Methods: Four different types of tablets of the same consistency (matrix and three-layered, with 5-ASA and dextran or pectin as excipients) were 
placed in a hard gelatin capsule. The 5-ASA release behavior from these formulations was compared to the release of the commercially available 
Asalazin®
Results: The produced tablet formulations conformed to the Pharmacopoeia standards. The results showed delayed-release (<10%) during the first 
two hours, in acidic media (pH 1.5), and modified-release thereafter (pH 6 and 7.4). When dextran was used, the drug release showed more 
extended-release characteristics, in comparison to pectin formulations, due to the formation of a thicker hydrogel. 
 in three pH aqueous media in the presence of enzymes.  
Conclusion: The new dosage forms could serve as a per os administration alternative dosage form for the delayed release of mesalazine to the colon 
Keywords: Mesalazine, Delayed release, Pectin, Dextran, Tablets-in-capsule, Pectinex®
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (
 Ultra SPL 
http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2020v12i4.37816. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
 
INTRODUCTION 
Irritable bowel syndrome (IBD) is a group of inflammatory 
conditions mostly specified in the intestinal area. Crohn's disease 
(CD) and Ulcerative colitis (UC) are the two most common forms of 
IBD, which affect millions of people worldwide. Even though UC and 
CD are two different diseases, they may have similar symptoms, such 
as abdominal pain, rectal bleeding and diarrhea. Their exact causes 
remain uncertain, but research suggests that the disease involves 
various genetic abnormalities, imbalance in intestinal microflora and 
environmental factors (lifestyle, stress levels, etc.) [1, 2].  
Mesalazine (5-aminosalicylic acid, 5-ASA) is a drug substance with 
anti-inflammatory activity, 
Campregher
used as the first-line drug treatment for 
the management of CD and UC. The exact mechanism of 5-ASA is not 
defined, but theory suggests that its anti-inflammatory properties 
are related to the therapeutic effect at the colon area [3]. Research 
indicates that 5-ASA exerts its effect locally in the inflamed colonic 
mucosa and not through systematic absorption. Long-term usage of 
5-ASA may be accompanied with adverse effects, such as drug 
intolerance and hypersensitivity. Furthermore, the 5-ASA’s 
electronic features are altered in the stomach, due to the acidic pH, 
and therefore, it becomes therapeutically inefficient in the targeted 
colon site [4] ( , Gasche, 2011). In view of this, 
researchers are designing novel orally administered 5-ASA 
formulations, using various excipients that delay the drug release to 
the targeted area. 5-ASA colon delivery systems can be achieved by 
various approaches; chemical modification of the drug molecule for 
prodrug production [5-10], but also pH/time dependent 
formulations and bacterial degradation [11-15], as a single unit or 
multiparticulate dosage forms [16-19].  
Scientists use multiparticulate dosage forms in order to control the 
5-ASA’s release. These pharmaceutical dosage forms, such as pellets 
and tablets that are further compressed into larger tablets or 
inserted to capsules, have many advantages, including less inter-and 
intra-variability and a higher degree of dispersion in the 
gastrointestinal tract [20, 21]. Multilayer tableting is another 
approach of drug release modification; multilayer tablets can be 
consisted of the same or different active pharmaceutical 
ingredient(s) and/or excipient(s) in each layer, and therefore, 
provide modified release kinetics. Drug release modification may 
also be attained by using various polymers [22, 23]. The hydrophilic 
polymeric excipients take up water, on exposure to aqueous media, 
and swell to form a gel layer. Using hydrogels, the drug release is 
controlled by diffusion barriers and surface erosions, depending on 
the polymeric network structure [24].  
When studying drug release in the intestinal area, it is of great 
importance to mimic the colon area micro-environment. Therefore, 
buffer solutions containing enzymes that are usually present in the 
gastrointestinal tract, are used.
As already mentioned, the objective of the present work is to 
formulate new delivery systems of 5-ASA for colon targeted release 
based on the combination of time and bacterial degradation 
approaches, 
 Many researchers have previously 
used enzymatic dispersions in dissolution tests in various 
concentrations; 86600PG/l [25], 44200PG/l [26], 61800PG/l [27, 
28], 45600 PG/l [29]. 
using capsules filled with tablets. The tablets were 
composed either of layers or of physical mixtures of excipients 
(dextran or pectin) and 
MATERIALS AND METHODS 
5-ASA.  
Materials 
5-ASA, dextran (from Leuconostoc mesenteroides, av. MW: 5x106-
40x106) and pectin were obtained from Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany. The commercially available drug 
Asalazin®, 500 mg enteric-coated tablets (Medichrome S. A., Athens, 
Greece), was obtained from a community pharmacy store. Pectinase 
from Aspergillus aculeatus (Pectinex®
Methods 
 Ultra SP-L) was donated by 
Novo Nordisk Hellas Ltd, Athens, Greece. 
Formulations’ preparation 
Multilayer and matrix tablets (6.5 mm diameter) were produced by 
direct compression using a hydraulic press (Carver 3393, Carcer Inc, 
Wabash, USA). The multilayer tablets consisted of three layers; the 
upper layer was formed from either pectin or dextran (25 mg), the 
internal layer contained 5-ASA (50 mg), and the lower layer was 
formed using either pectin or dextran (25 mg). Matrix tablets 
consisted of a mixture of 5-ASA (50 mg) and either pectin or dextran 
(50 mg). Four identical tablets were used to fill the hard gelatin 
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(Syndesmos SA, Athens, Greece) and enteric-coated size zero 
(Capsugel, Colmar, France) capsules. 
Characterization of tablets (weight, thickness, crushing 
strength uniformity and friability test) 
The weight uniformity was determined on 10 samples for each 
tablet formulation; the mean value and the standard deviation 
(SD) were calculated and expressed in mg. The tablets’ thickness 
was determined on 10 samples for each tablet formulation on a 
Vernier caliper; the mean value (±SD) was calculated and 
expressed in mm.  
The tablets’ crushing strength was measured with a hardness tester 
(Erweka 24992 TBH 28, Erweka Gmbh, Heusenstamm, Germany). 
Ten samples of each tablet formulation were evaluated; the mean 
hardness (±SD) was calculated and expressed in kp. 
Tablet friability has been determined on 10 samples for each tablet 
formulation using a friabilator (Erweka, type TA3R Gmbh, 
Heusenstamm, Germany). The friability was expressed in terms of 
weight loss and calculated as % of the initial weight; friability under 
1% was considered acceptable. 
In vitro drug release studies in stimulated gastrointestinal fluids 
The release of 5-ASA from each formulation was tested using a 
dissolution paddle apparatus (PharmaTest-D17, Hainburg, Germany). 
The consistency of the dissolution media used is depicted in table 1. 
Samples were withdrawn at predetermined time intervals, filtered and 
analyzed using a UV-1700 PharmaSpec spectrophotometer (Kyoto, 
Japan). The dissolution experiments were performed in triplicate. In 
order to test the effect of the colonic enzymes, the dissolution tests 
were performed again, but this time with the addition of 45600 PG/l 
Pectinex® Ultra SPL in the final dissolution medium. To evaluate the 
dissolution profiles, 5-ASA % release (mean±SD) vs time graphs were 
constructed using GraphPad Prism 3.0, t20%, t50% t90%, (times at 20%, 
50% and 90% 5-ASA release) and the values of Mean Dissolution Time 
(MDT) [30] and Dissolution Efficiency (D. E. %) [31] were recorded. 
Furthermore, D. E % results were analyzed using the Student’s t-test 
(P<0.05) and the comparison indices (difference (f1) and similarity 
(f2
RESULTS AND DISCUSSION 
) factors) were also calculated [32, 33]. 
The results of weight, thickness, crushing strength uniformity and 
the friability test are depicted in table S1. All formulations were 
found to meet the Pharmacopoeia standards [34]. 
As previously reported [35, 36] 5-ASA (fig. 1, structure Ι) in the acidic 
environment (pH 1.5) is transformed to structure (ΙΙ) due to NH2
 
 
protonation. As a result, 5-ASA’s solubility, at this pH, is enhanced 
(around 3 mg/ml). In the non-acidic environment (pH around 7), its 
solubility becomes even higher due to its transformation to structure 
(ΙΙΙ). In this case, its solubility is approximately 18 mg/ml. Conversely, in 
the pH region 2.2<pH<5.5, its amphoteric structure IV (fig. 1) prevails. 
The prevalence of the particular structure of 5-ASA, in this pH region, 
leads to reduced solubility (around 1 mg/ml) [37].The use of enteric-
coated tablets delayed the 5-ASA’s initial release; in the first 2 h, in the 
acidic medium, no drug release was observed. Conversely, hard gelatin 
capsules dissolved immediately after their contact with the aqueous 
media releasing the containing tablets instantly. 
 
Fig. 1: Chemical structures of 5-ASA at various pHs [35,36] 
 
 
Fig. 2: % Release (mean±SD) (n=3) of 5-ASA vs time (min) from capsules containing four 3-layered tablets with pectin (a) and dextran (b), 
four tablets containing mixtures of pectin (c) and dextran (d), from simple ( ○) or enteric-coated capsules ( ●) and Asalazin® (×) in pH media 
(—) or in pH media where the enzymatic solution is added (---) 
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Table 1: Experimental parameters for in vitro drug release 
Simulated area of the GI 
tract 
pH Final dissolution medium 
(ml) 
Solution added: pH/volume 
(ml) 
Time from the test start 
(min) 
Stomach 1.5 400 S1: 1.5/400 0-120 
Small intestine 7.4 800 S2: 9.4/400 120-300 
Large intestine 6.0 1000 S3: 1.5/200 300-720 
 
Pectin and dextran polymers, when in contact with the aqueous fluids, 
swell and turn into a hydrogel that act as a barrier to drug release. 
Comparing the drug release through these two different polymeric 
layers, it could be concluded that pectin produced a thinner layer than 
dextran allowing for faster drug dissolution. The t20%, t50%, t90%
 
 and MDT 
values were lower when pectin was used (table 2), demonstrating a 
more rapid drug release. Pectin hydrogels release the entrapped drug 
through diffusion [38]. Dextran hydrogels showed very promising 
modified release characteristics, as they also have with other active 
ingredients, such as hydrocortisone, peptide and protein drugs [39-41]. 









t20% t50% MDT 90% D. E.(%) 
1c c Pectin Four  
3-layered 
Tablets in capsule 
 
- 200 310 460 330.58 58.25 (±0.64) 
1c-X √ 200 310 400 280.65 59.99 (±0.87) 
1ec ec - 250 330 600 391.29 49.82 (±0.35) 
1ec-X √ 250 310 460 335.98 57.5 (±0.18) 
2c c Dextran - 310 360 540 369.24 48.59 (±0.4) 
2c-X √ 310 340 460 369.68 52.82 (±0.36) 
2ec ec - 355 420 >720 436.78 34.68 (±0.63) 
2ec-X √ 340 380 570 428.93 44.59 (±0.74) 
3c c pectin Four mixture 
tablets in capsule 
- 140 235 475 289.77 64.58 (±0.34) 
3c-X √ 140 230 340 258.97 68.19 (±0.87) 
3ec ec - 310 330 510 354.52 50.57 (±0.24) 
3ec-X √ 310 330 355 351.02 55.41 (±0.17) 
4c c dextran - 310 360 660 396.82 44.46 (±0.72) 
4c-X √ 310 340 460 334.25 53.58 (±0.24) 
4ec ec - 330 530 720 463.75 32.41 (±1.13) 
4ec-X √ 330 450 570 451.32 41.48 (±0.86) 
Asalazin® - 130 150 160 150.00 79.17 (±0) 
c: hard gelatin capsule, ec: enteric-coated capsule) used and Asalazin®500 mg, the experimental conditions during dissolution (presence 
(√)/absence (-) of Pectinex® Ultra SPL), time at 20%, 50% and 90% of drug release (t20%, t50% and t90%
 
), the Mean Dissolution Time (MDT) and the 
Dissolution Efficiency D. E.(%) (mean±SD) (Number of experiments, n=3) 
Table S1: Results of weight, thickness, crushing strength uniformity and friability test 
Formulation Weight (mg) Thickness (mm) Crushing test (kp) % Friability 
1 3L-P 101.2±1.2 1.88±0.32 11.58±0.56 0.51 
2 3L-D 100.3±0.9 1.81±0.11 12.01±0.43 0.46 
3 Matrix-P 101.2±1.3 1.82±0.31 11.94±0.56 0.68 
4 Matrix-D 100.1±0.8 1.79±0.24 12.13±0.28 0.75 
3L-P: 3layered tablet with pectin, 3L-D: 3layered tablet with dextran, Matrix-P: matrix tablet with pectin, Matrix-D: matrix tablet with dextran. 
Values indicated in weight, thickness and crushing tests are mean±SD, number of experiments, n=10. 
 
Table S2: f1 and f2 
Formulation 
indices and P-value of ANOVA comparison of D. E.(%) 
f f1 P-value D. E.(%) 2 
1c vs 1c-X 10.28 54.44 P<0.001 
1ec vs 1ec-X 19.46 42.84 P<0.001 
2c vs 2c-X 18.88 41.99 P<0.001 
2ec vs 2ecX 23.11 39.89 P<0.001 
3c vs 3c-X 13.54 49.91 P<0.001 
3ec vs 3ec-X 16.65 45.31 P<0.001 
4c vs 4c-X 26.02 35.36 P<0.001 
4ec vs 4ec-X 26.43 35.37 P<0.001 
 
The fact that at the gastric environment (pH 1.5) the 5-ASA % 
release from pectin containing capsules is higher than in the 
respective dextran formulations is probably due to the presence of 
the methyl ester groups in pectin, which form hydrogen bonds with 
the-NH2 In most cases, when matrix tablets were used, the 5-ASA’s release rate 
was faster than from the 3-layered tablets (comparison of the times t 
 and-OH groups of 5-ASA, thus facilitating its solubility. In 
the case of the more esterified pectins, this effect is more 
pronounced, as the number of the non-esterified-COOH groups is 
less. Conversly, in the case of dextran, which bears secondary-OH 
groups, the above hydrogen bond-due solubility enhancing effect is 
much less important. 
20%, 
t 50% and t 90% in table 2). This could be attributed to the gel layer 
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produced from the outer tablet’s layers that are exclusively composed 
of the polymer, thus retarding the 5-ASA’s release. 
Asacol®
The enzyme-triggered 5-ASA release was evaluated by the addition of 
an enzymatic solution to the dissolution media; both hydrogels 
produced by dextran and pectin have a potential for specific delivery 
to the colon by undergoing degradation at the site, allowing drug 
release only in the case that microbial enzyme(s) is/are present at the 
colonic area. Drug release was lower in the medium, which did not 
contain the enzymatic solution, as the excipients’ gel layer remained 
thicker, and a longer time was needed for its erosion, resulting to 
reduced drug release. Conversely, the addition of the enzymatic 
solution, at 300 min, increased the 5-ASA’s release in all cases (most of 
f
 encapsulates 5-ASA in an enteric coat, which consists of a 
resin film that is intended to release the active pharmaceutical 
ingredient only at a designated pH. That way the site of drug release 
can be controlled. The coating is the methacrylate copolymer 
Eudragit-S, which allows 5-ASA’s release at pH ≥ 7 [42]. A possible 
concern with this type of drug delivery systems is that the intestinal 
pH varies in patients with IBD [43], setting back the 5-ASA released 
from the pH-dependent enteric coating and reduce its efficacy.  
1 and f2 indices showed different release rates and the comparison of 
D. E.(%) values showed significantly different results, P<0.05 (vide 
table S2). The increased release noticed was mainly ascribed to the 
cleavage of the polymeric bonds of pectin and dextran. Similar results 
have been mentioned in the literature [35, 44]. Asalazin®
CONCLUSION 
 500 mg 
tablets were not tested with the enzymatic solution, as 100% release 
was achieved within 180 min (fig. 2, table 2).  
Enzymatically sensitive formulation systems were produced with 5-
ASA and pectin or dextran, as excipients. The results showed 
delayed-release,<10% during the first two hours and modified-
release thereafter. When dextran was used, the drug exhibited an 
extended-release profile, due to the thicker hydrogel produced in 
comparison to the pectin formulations. The data obtained revealed 
that the release of 5-ASA, from the 3-layered tablets, is slower when 
compared to the matrix tablets. 
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